Millennium Pharmaceuticals, Inc., a Takeda Company, 35 Landsdowne St., Cambridge, MA 02139, USA.
J Neuroimmunol. 2013 Nov 15;264(1-2):123-6. doi: 10.1016/j.jneuroim.2013.08.011. Epub 2013 Aug 31.
Vedolizumab, a gut-homing α4β7 integrin antagonist, has demonstrated efficacy in ulcerative colitis and Crohn's disease. Development of progressive multifocal leukoencephalopathy, a serious brain infection associated with natalizumab (an α4β7 and α4β1 integrin antagonist), has raised concern that vedolizumab may convey a similar risk. Natalizumab is believed to impair central nervous system immune surveillance by affecting cerebrospinal fluid (CSF) lymphocyte counts and the CD4:CD8 ratio. To determine if vedolizumab elicits similar effects, we examined CSF of healthy volunteers by flow cytometry for T-lymphocyte surface markers 5 weeks after administration of intravenous vedolizumab 450 mg. No significant changes were observed in CSF T-lymphocyte populations.
维得利珠单抗是一种靶向肠道归巢的 α4β7 整合素拮抗剂，已被证实对溃疡性结肠炎和克罗恩病有效。与那他珠单抗（一种 α4β7 和 α4β1 整合素拮抗剂）相关的进行性多灶性白质脑病是一种严重的脑部感染，其发展引起了人们的担忧，即维得利珠单抗可能带来类似的风险。那他珠单抗被认为通过影响脑脊液（CSF）中的淋巴细胞计数和 CD4:CD8 比值，从而损害中枢神经系统的免疫监视。为了确定维得利珠单抗是否会产生类似的影响，我们在静脉注射维得利珠单抗 450mg 5 周后，通过流式细胞术检查了健康志愿者的 CSF 中的 T 淋巴细胞表面标志物，并未观察到 CSF T 淋巴细胞群有显著变化。
